New drug cocktail aims to beat back tough leukemia
NCT ID NCT03629171
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether combining two drugs—CPX-351 (a chemotherapy) and venetoclax (a targeted therapy)—can help people with acute myeloid leukemia (AML) that has come back or not responded to prior treatment. About 52 adults will take part at MD Anderson Cancer Center. The goal is to see if this combo can achieve remission and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPX-351 (a liposomal combination of two chemotherapy drugs, daunorubicin and cytarabine) and venetoclax (a targeted drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with AML that has come back or not responded to other therapies.
What could go wrong
This is a small, early-phase (Phase II) trial, so results may not apply broadly. Side effects from chemotherapy and venetoclax can be serious, including infection and bleeding risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact